Safety and Effectiveness of Secukinumab in Japanese Patients with Psoriasis and Psoriatic Arthritis
Author Information
Author(s): Fujishige Ayako, Seko Noriko
Primary Institution: Novartis Pharma K.K.
Hypothesis
This study aims to evaluate the long-term safety and effectiveness of secukinumab in patients with psoriasis vulgaris and psoriatic arthritis in Japan.
Conclusion
The surveillance results confirm the long-term effectiveness of secukinumab treatment in patients with psoriasis vulgaris and psoriatic arthritis, with no new safety concerns reported.
Supporting Evidence
- 36.17% of patients reported adverse events during the study.
- 71.62% of patients were treated for psoriasis vulgaris.
- 77.36% of patients showed improvement in their skin condition by week 24.
- Patients with a history of biologics had lower response rates compared to those without.
- The mean duration of secukinumab administration was 288.1 days.
Takeaway
This study looked at how well a medicine called secukinumab works for people with skin problems and joint pain, and it found that it helps a lot without causing new problems.
Methodology
This was an open-label, multicenter, single-arm, prospective observational surveillance study.
Potential Biases
The study did not account for confounding factors due to incomplete data.
Limitations
The study was observational without a control group and did not collect information on patients not exposed to secukinumab.
Participant Demographics
The majority of participants were adults aged 18 years and older, with a mean age of 54.1 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website